Overview

Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease

Status:
Terminated
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
Clinical features in patients with the familial early onset forms and the sporadic forms of Alzheimers disease are similar, although the course of deterioration may be different. It would be very informative to examine the drug response of patients with Alzheimers disease by a certain genotype to find evidence favouring genotype-specific drug responses that may indicate genetically defined phenotypic differences in alzheimers disease.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Rosiglitazone